Nano Miscellaneous
Market Cap
₹221 ₹221 Cr.
P/E
43.29
PEG = P/E ÷ 5yr Forward EPS CAGR

The forward EPS CAGR is estimated individually for each company - factoring in its guidance, industry, and growth drivers - not generic rule-based projection.

Key Ratios

Debt to Equity
Debt to Equity
0.10
Div Yield (%)
Div Yield (%)
-
Individual < 2 lac
Individual < 2 lac
11.65 %
Institutions
Institutions
0.70 %
Market cap
Market cap
221 Cr
No. of Shareholders
No. of Shareholders
933
OPM (%)
OPM (%)
-
PE
PE
43.29
Prom Holding
Prom Holding
74.05 %
ROCE (%)
ROCE (%)
15.43
ROE (%)
ROE (%)
7.35
Sales
Sales
55.13 Cr
  • Aprameya Engineering
  • Novelix Pharma
  • Gujjubhai Industries
Last updated on 8 May 2025
  • Aprameya supplies turnkey healthcare projects and medical-equipment trading with embedded services.
  • Shifted from mixed trading and emerging turnkey work to turnkey-dominated model.
  • FY25 rebounded sharply on concentrated turnkey execution, including ₹112.5Cr Maharashtra order; 18% margin reflects that mix.
  • Earnings ride turnkey project supplies at ~92% of operating revenue; trading small, recurring maintenance yet to scale.
  • Geographic expansion underway; recurring maintenance revenue targeted.
  • Cash conversion lags profit; receivables ₹119.1Cr, operating cash flow negative ₹10.6Cr, cash thin despite IPO deleveraging.
  • Near term turns on fresh order wins; one customer was 83% of FY25 revenue; tender and OEM dependence persist.
  • Order-book replacement Next results or order filing; 5–6 month window elapsed
    fresh order value, customer mix, state mix and executable period become visible.
  • Working-capital normalization Q1FY27–FY27 results
    receivables, loss allowances, work-in-progress and cash flow show if sales convert to cash.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
102
52W Range
High
360
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

8 Yes

Positive for this company

2 Neutral

Neutral for this company

6 No

Negative for this company

1 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Peer Comparison

FAQs on Aprameya Engineering Ltd. Business

Aprameya Engineering is engaged in the business of installation, set up &amp; maintenance of Intensive Care Units (ICU), Neonatal Intensive Care Units (NICU), Pediatric Intensive Care Units (PICU), Operation Theatre and prefabricated structure ward in the hospitals and medical care centres on turnkey basis along with supply of high value healthcare equipment and diagnostic equipment to private hospitals, Government hospitals and medical practitioners.

Aprameya Engineering major competitors are Novelix Pharma, Jullundur Motor Agen, Sicagen India, Equippp SocialImpact, Sakuma Exports, Gujjubhai Industries, Northern Spirits.
Market Cap of Aprameya Engineering is ₹221 Crs.
While the median market cap of its peers are ₹219 Crs.

Aprameya Engineering seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

Company Filing

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
Earnings Release
Investor Presentation
Conference Call
Conference Call SummaryCon Call Summary

Discussions & Analysis

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material